By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


SEARCH JOBS

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at www.oncogenex.com

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678



Key Statistics


Email:
Ownership: Public

Web Site: OncoGenex Pharmaceuticals Inc.
Employees:
Symbol: OGXI
 









Company News
OncoGenex Pharmaceuticals Inc. (OGXI) And Sarah Cannon Research Institute Announce Completion Of Patient Enrollment In The Spruce Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer 2/24/2015 7:51:52 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years 2/13/2015 6:52:58 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer 1/16/2015 9:20:54 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Snags $27 Million and Prostate/Lung Cancer Rights From Teva Pharmaceutical Industries Limited (TEVA) 12/30/2014 7:36:48 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Results From The Phase 2 Borealis-1 Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer 12/19/2014 8:01:43 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANEв Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer 12/16/2014 9:57:49 AM
OncoGenex Pharmaceuticals Inc. (OGXI) To Present At The Stifel 2014 Healthcare Conference 11/17/2014 11:43:27 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Third Quarter 2014 10/31/2014 7:40:31 AM
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Third Quarter 2014 On October 30, 2014 10/16/2014 7:21:14 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-Line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer 9/16/2014 8:10:45 AM
12345678910...
//-->